



## ASX Release

### MUTUAL TERMINATION OF CONSULTING CONTRACTS

**Melbourne, Australia: 22 July 2019:** Jayex Healthcare Limited (**ASX:JHL**) (**JHL** or **Company**) today announces the mutually agreed termination on 21 July 2019 of the two consulting agreements JHL and its subsidiaries have with Ross Smith and his company Weed Inc. Limited.

The two contracts are:

- (a) the Consulting Agreement, dated 24 July 2018, between JHL, its wholly-owned subsidiary MC2U Pty Ltd (ACN 627 330 018) (MC2U) and Ross Smith; and
- (b) the MC Genetics Licence & Grow Program Services Agreement, dated 7 December 2018, between JHL, its wholly-owned subsidiaries, MC2U and MCannNZ Limited (now Whakaora Hou Limited) (Company No: 7146193) (WHL), Weed Inc. Limited (Company No: 7170653) and Ross Smith.

Mr Smith has advised the Company of his intention to open a classic motor cycle shop in Tauranga and his cannabis genetics company, Weed Inc Limited, has accepted an attractive medical cannabis opportunity in Malaysia and is pursuing another Colombian opportunity. These latter arrangements would present a conflict of interest with his contractual commitments to the Jayex Group in medical cannabis genetics and related consulting services.

Accordingly, JHL and Mr Smith have agreed the mutual termination of both consulting contracts and related confidential termination arrangements. All unvested performance rights for Mr Smith that were on issue have now lapsed.

The Company wishes Mr Smith well with his new ventures.

**Ends**

#### Contacts for further information:

##### Media Enquiries

Melissa Hamilton  
Media + Capital Partners  
+61 417 750 274  
[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

##### Investor Enquiries

Chief Executive Officer	Company Secretary
Nick Fernando	Melanie Leydin
1300 330 611	+61 3 9692 7222
<a href="mailto:n.fernando@jayex.com">n.fernando@jayex.com</a>	

#### Forward looking statements

This announcement contains forward-looking statements. All statements that address events or developments that we expect or anticipate will or may occur in the future are forward-looking statements. These forward-looking statements are based on the Board or management's beliefs and expectations based on information currently available to the Board and management. The Company believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking

statements which are inherently uncertain. The Company does not undertake any obligation to publicly update or revised any forward-looking statements whether as a result of new information, future events or otherwise except as required by law or the ASX Listing Rules. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from the Company's historical experience, or present expectations or projections.

About Jayex Healthcare Limited - [www.jayexhealthcare.com.au](http://www.jayexhealthcare.com.au)

---

Jayex Healthcare is a leading provider of integrated healthcare services delivery platforms in the United Kingdom and Australia, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
  - the *Appointuit* patient engagement solution;
  - the *Pharmacy Delivery 2 U (P2U®)* prescription delivery service; and
  - the *BluePoint®* remote pharmacy prescription processing and dispensing terminal.
-